Aspiring biotech businesses looking to gain a foothold in the fledgling European medical cannabis industry should take a leaf from their Canadian counterparts on intellectual property, say specialist life sciences patent attorneys Micheline Gravelle and Jane Wainwright.
Potter Clarkson is delighted to announce that it has secured a global settlement for its client Alnylam Pharmaceuticals, Inc., the world’s leading RNAi therapeutics company, of worldwide litigation with Silence Therapeutics PLC.
Potter Clarkson is delighted to announce the relocation of its Stockholm office to new and larger premises.
In November, the UK Supreme Court ruled that Warner-Lambert’s patent for a second medical use of pregabalin for the treatment of pain is invalid for insufficiency of disclosure. Sheena Linehan explores the lessons for patent drafting.
Potter Clarkson is delighted to announce that it has joined a limited number of companies in becoming an official affiliate partner of the Graphene Engineering Innovation Centre, a £60 million pound research centre run by the University of Manchester as part of their vision of building a Graphene City.
Second medical use patents have taken a blow with the Supreme Court’s recent ruling in Warner-Lambert v Mylan and Actavis. Sheena Linehan reports on the ruling and considers its impact on the life sciences sector.